Removal of Syndecan-1 Promotes TRAIL-Induced Apoptosis in Myeloma Cells

Institute of Microbiology and Immunology, National Yang-Ming University, Taipei 11221, Taiwan.
The Journal of Immunology (Impact Factor: 4.92). 03/2012; 188(6):2914-21. DOI: 10.4049/jimmunol.1102065
Source: PubMed


Syndecan is the major transmembrane proteoglycan in cells. Of the four syndecans, syndecan-1 is the dominant form expressed in multiple myeloma and is an indicator of poor prognosis. In the current study, we observed that early TRAIL-induced apoptotic processes were accompanied by cleavage of syndecan-1 intracellular region, and explored the possibility whether removal of syndecan-1 promotes apoptotic processes. We found that syndecan-1 knockdown by specific small interfering RNA in multiple myeloma enhanced TRAIL-induced apoptosis, even though the expression of TRAIL receptors and several apoptosis-associated molecules was unaffected. The enhanced TRAIL-mediated apoptosis in syndecan-1-deficient cells was not due to a decrease in surface heparan sulfate or a reduction in TRAIL receptor endocytosis. The increase in TRAIL-induced cell death was accompanied by an elevated caspase-8 activation and an enhanced formation of death-inducing signaling complexes, which could be attributed to an increased expression of TRAIL receptor O-glycosylation enzyme in syndecan-1-deficient cells. We also found that in H9 lymphoma and Jurkat cells, knockdown of the predominant syndecan member also led to an increase in Fas ligand-induced apoptosis. Our results demonstrate that syndecan plays a negative role in death receptor-mediated cell death, suggesting potential application of syndecan downregulation in the treatment of myeloma in combination with TRAIL.

Download full-text


Available from: Chen-Ying Yang, Jul 19, 2014
  • Source
    • "O-linked glycosylation of DR5 is catalyzed by N-acetyl-galactosamine (GalNAc) transferase (GALNT) 3, GALNT14, and ␣-(1,3)-fucosyltransferase (FUT), transferring GalNAc to serine and threonine residues in the polypeptide extracellular domain (Wagner et al., 2007). O-glycosylation is suggested to increase membrane stability of the receptors, preventing endocytosis (Wu et al., 2012), and facilitating receptor translocation into clusters for DISC assembly and caspase-8 activation (Wagner et al., 2007; Wu et al., 2012). Increased levels of the glycosylated proteins directly correlate with TRAIL sensitivity in colorectal, pancreatic, non-small cell lung cancer (NSCLC), and melanoma cell lines (Wagner et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: TNF-related apoptosis inducing ligand (TRAIL) selectively induces apoptosis in cancer cells without harming most normal cells. Currently, multiple clinical trials are underway to evaluate the antitumor activity of recombinant human TRAIL (rhTRAIL) and agonistic antibodies that target death receptors (DRs) 4 or 5. It is encouraging that these products have shown a tolerated safety profile in early phase studies. However, their therapeutic potential is likely limited by the emergence of tumor drug resistance phenomena. Increasing evidence indicates that TRAIL DRs are deficient on the plasma membrane of some cancer cells despite their total protein expression. Notably, the lack of surface DR4/DR5 is sufficient to render cancers resistant to TRAIL-induced apoptosis, regardless of the status of other apoptosis signaling components. The current review highlights recent findings on the dynamic expression of TRAIL death receptors, including the regulatory roles of endocytosis, autophagy, and Ras GTPase-mediated signaling events. This information could aid in the identification of novel predictive biomarkers of tumor response as well as the development of combinational drugs to overcome or bypass tumor drug resistance to TRAIL receptor-targeted therapies. Published by Elsevier Ltd.
    Full-text · Article · Mar 2015 · Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy
  • Source
    • "An influence of Sdc-1 on the Akt-pathway was also described for prostate cancer cells (Hu et al., 2010). Another study about the role of Sdc's in death receptor mediated cell death of multiple myeloma cells described that Sdc-1 kd enhanced the sensitivity to TRAIL-induced apoptosis, while Sdc-2 and -4 kd increased the sensitivity to FasL (Wu et al., 2012). In spite of the contrary literature an influence of Sdc-1 kd in EEC apoptosis by modulation of MAPK, "
    [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial epithelial cells are known to undergo apoptosis during trophoblast invasion. We postulate that the cell surface molecule Syndecan-1 which is expressed on endometrial cells and syncytiotrophoblast is important for implantation in general and especially for induction of maternal cell apoptosis during trophoblast invasion because Syndecan-1's influence on apoptotic susceptibility of cancer cells is already described in the literature. Using the human endometrial epithelial cell line RL95-2, a new stable cell line with Syndecan-1 knock down was generated. Via antibody array analysis, a significant decrease in the expression of anti-apoptotic proteins like inhibitors of apoptosis ( IAPs), Clusterin, heme oxygenase (HO-2), heat shock protein (HSP)27 and -70 and Survivin due to the Syndecan-1 knock down was discovered. Correspondingly, active Caspase-3 as an indicator for apoptosis was increased more severely in these cells compared to unmodified RL95-2 after treatment with implantation related stimuli, which are the cytokines interleukin (IL)-1β, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β1 and an anti-Fas antibody. Furthermore, a treatment with a combination of all factors caused a higher Caspase-3 induction compared to each single treatment. These results demonstrate that Syndecan-1 is involved in the control of apoptosis in RL95-2 cells and therefore may affect the fine tuning of apoptosis in endometrial epithelium regulating the embryo's invasion depth as a crucial step for regular implantation followed by successful pregnancy.
    Full-text · Article · Jan 2014 · Molecular Human Reproduction
  • [Show abstract] [Hide abstract]
    ABSTRACT: Syndecans are among those transmembrane PGs which act via their heparan sulphate chains as receptors for different matrix elements (e.g. collagen I–III, fibronectin, thrombospondin, tenascin) and co-receptors for growth factors (e.g. bFGF, aFGF, GM-CSF, IL-3, IFNg). We hypothesized that there is a positive relationship between the expression of syndecan-1 (CD138) and treatment response in non-Hodgkin’s lymphoma. To identify the expression of syndecan-1 (CD138) in cases of non-Hodgkin’s lymphoma and to correlate its expression with treatment response and disease stage, this study was carried out as a cross-sectional study and included 30 patients with non-Hodgkin’s lymphomas attending Suez Canal University Hospital; diagnosis of patients was made by routine histological and immunohistochemical examination. CD138 mRNA expression was assessed by TaqMan technique using real-time PCR method. There was increased expression of CD138 mRNA in patients with follicular lymphoma than in patients with diffuse large B cell lymphoma (6.25 versus 3.46, respectively) (p ≤ 0.05). Syndecan-1 (CD138) mRNA expression from peripheral blood may be a useful marker for follicular lymphoma and can be used as a marker of treatment response in patients with follicular and diffuse large B cell lymphoma.
    No preview · Article · Jul 2013 · Comparative Clinical Pathology
Show more